AzTrials
AzTrials

Auditory HallucinationsPhase 2TBS-HNCT01478880

Efficacy and Safety of Bilateral Theta Burst Stimulation for the Treatment of Auditory Hallucinations

A Phase 2 study testing continuous theta burst stimulation (cTBS) in people with Auditory Hallucinations, run by University Hospital Tuebingen at 1 site in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

First clinical studies indicate an effect of repetitive transcranial magnetic stimulation(rTMS) in the treatment of auditory hallucinations (AH). However, effect size, optimal stimulation site and parameters are unclear. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Auditory Hallucinations
What is being tested?
continuous theta burst stimulation (cTBS)
Type of treatment
Surgery or procedure
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
16 participants
Where
1 siteGermany
Study dates
May 2011to Jul 2013
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • auditory hallucinations at least once a week
  • Schizophrenia (DSM-IV)
  • stable treatment setting (in- or out-patient)
  • no change of antipsychotics during and at least 1 week before treatment initiation

Who cannot join

  • epilepsy
  • benzodiazepines > 1,5mg lorazepam / d
  • pregnancy
  • metal parts in the brain
  • cardiac pacemaker
  • deep brain stimulation

Trial locations and contacts

1 site in 1 country.

Germany1 site
  • University of Tübingen, Department of Psychiatry and Psychotherapy

    Tübingen

Other trials in Germany

About this study

Official title: Efficacy and Safety of Bilateral Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation) for the Treatment of Auditory Hallucinations

First clinical studies indicate an effect of repetitive transcranial magnetic stimulation(rTMS) in the treatment of auditory hallucinations (AH). However, effect size, optimal stimulation site and parameters are unclear. With this randomized, placebo-controlled clinical trial we test the efficacy and safety of bilateral continuous theta burst stimulation (cTBS), a patterned form rTMS, against auditory hallucinations. The treatment will be applied add-on to individual antipsychotic and behavioral therapy. Patients will be treated for 6 weeks each weekday (30 sessions) with 40s of cTBS (halfway between T3/P3 and T4/P4). For weeks 1-3, half of the subjects will be randomized to a sham-stimulation (coil tilted 45°). During weeks 4-6, all subjects receive real cTBS.

Being tested
continuous theta burst stimulation (cTBS), sham cTBS
Medical subject headings
Hallucinations

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • continuous theta burst stimulation (cTBS)Procedure or surgery

    bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4)

  • sham cTBSProcedure or surgery

    bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4) with the stimulation coil tilted 45°

Study groups in NCT01478880
Study groupRoleWhat they receive
cTBSExperimentalNot described
Receives: Procedure: continuous theta burst stimulation (cTBS)
Sham cTBSSham comparatorNot described
Receives: Procedure: sham cTBS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Psychotic Symptom Rating Scales (PSYRATS), subscale for auditory hallucinations

    Change of PSYRATS AH score compared to baseline after 3 weeks of treatment

    Measured: 3 weeks

Secondary outcomes (3)
  1. Hallucination change score (HCS)

    Measured: 3 and 6 weeks

  2. Positive and Negative Symptom Scale (PANSS)

    Measured: 3 and 6 weeks

  3. PSYRATS subscale for auditory hallucinations

    Change of PSYRATS AH score compared to baseline after 6 weeks of treatment

    Measured: 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Nov 2011 (estimated)
  2. Study startMay 2011
  3. Primary completionJul 2013
  4. Study completionJul 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
16 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01478880
Sponsor's protocol ID
TBS-H 1
Acronym
TBS-H
Status last verified
Jul 2013
First submitted
21 Nov 2011
Last updated
16 Jul 2013
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing continuous theta burst stimulation (cTBS) in people with Auditory Hallucinations, run by University Hospital Tuebingen at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Jul 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Psychotic Symptom Rating Scales (PSYRATS), subscale for auditory hallucinations (time frame: 3 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in